cbdMD agrees to buy Twinlab assets via creditor process, issuing 19.9% new shares
On September 1, 2026, cbdMD agreed to acquire assets of Twinlab through an assignment for the benefit of creditors, subject to court approval. The consideration is assumption of about $1.75 million of debt owed to Akretive Holdings plus 2,229,805 new common shares, equal to 19.9% of outstanding stock, which dilutes existing shareholders. The company also cut the conversion price of its Series B preferred stock from $1.00 to $0.60, effective September 2, 2026.
Key points
- Consideration: assumption of about $1,750,000 of debt owed to Akretive Holdings, plus 2,229,805 common shares (19.9% of outstanding shares at signing).
- Deal runs through an assignment for the benefit of creditors; closing requires a sale order from the ABC Court. The company expects to complete the deal in its first fiscal quarter.
- Company states combined unaudited trailing twelve-month revenue to June 2026 of about $30 million, about 40% above cbdMD standalone revenue for the same period; it says this figure is illustrative only.
- Series B conversion price cut from $1.00 to $0.60 effective September 2, 2026; 591,207 Series B shares are outstanding.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.